• Can Ozempic Maker Novo Nordisk Keep Up Its Momentum?

  • May 2 2024
  • Length: 13 mins
  • Podcast
Can Ozempic Maker Novo Nordisk Keep Up Its Momentum? By cover art

Can Ozempic Maker Novo Nordisk Keep Up Its Momentum?

Listen for free

View show details

  • Summary

  • A.M. Edition for May 2. Danish pharmaceutical giant Novo Nordisk upped its full-year guidance today as it reported continued strong demand for its blockbuster weight-loss and diabetes drugs. Barclays analyst Emily Field discusses where the drugmaker could go from here. Plus, Exxon Mobil reaches an agreement to close its $60 billion merger with Pioneer. And TikTok strikes a licensing deal to return Universal Music artists to the platform. Luke Vargas hosts. Listening on Google Podcasts? Here's our guide for switching to a different podcast player. Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show more Show less
Politics & Government
Show more Show less

What listeners say about Can Ozempic Maker Novo Nordisk Keep Up Its Momentum?

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available